Decibel Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference
Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company focused on hearing and balance treatments, announced that CEO Laurence Reid, Ph.D., will present at the Needham Virtual Healthcare Conference on April 15, 2021, at 4:30 PM ET.
A live webcast can be accessed via the Investors and Media section of their website, with an archived replay available for 90 days post-presentation.
Decibel is advancing gene therapies for congenital and acquired hearing loss, leveraging a proprietary platform that includes precision gene therapy technologies.
- None.
- None.
BOSTON, April 08, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid, Ph.D., Chief Executive Officer of Decibel, will present at the Needham Virtual Healthcare Conference on Thursday, April 15, 2021 at 4:30 pm ET.
A live webcast of the presentation may be accessed by visiting the Investors and Media section of the Decibel Therapeutics website at https://ir.decibeltx.com. An archived replay of the webcast will be available on the Company’s website for approximately 90 days following the presentation.
About Decibel Therapeutics
Decibel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, one of the largest areas of unmet need in medicine. Decibel has built a proprietary platform that integrates single-cell genomics and bioinformatic analyses, precision gene therapy technologies and expertise in inner ear biology. Decibel is leveraging its platform to advance gene therapies designed to selectively replace genes for the treatment of congenital, monogenic hearing loss and to regenerate inner ear hair cells for the treatment of acquired hearing and balance disorders. Decibel’s pipeline, including its lead gene therapy program, DB-OTO, to treat congenital, monogenic hearing loss, is designed to deliver on our vision of a world in which the privileges of hearing and balance are available to all.
Investor Contact:
Julie Seidel
Stern Investor Relations, Inc.
julie.seidel@sternir.com
212-362-1200
Media Contact:
Chris Railey
Ten Bridge Communications
chris@tenbridgecommunications.com
617-834-0936
FAQ
When is Decibel Therapeutics' presentation at the Needham Virtual Healthcare Conference?
How can I watch Decibel Therapeutics' presentation online?
What is the focus of Decibel Therapeutics' research?
What is the ticker symbol for Decibel Therapeutics?
What therapies is Decibel Therapeutics developing?
